Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Timing Of Midazolam İn Children Undergoing Adenotonsillectomy: Effects On Stress, Cortisol, And Recovery (Timing-Midazol)

7 de junho de 2026 atualizado por: Mehmet Sercan Orbak, Erzurum City Hospital

Optimization of Midazolam Administration Timing in Pediatric Adenotonsillectomy: Effects on Cortisol Response, Behavioral Stress, and Recovery Quality

This study is a prospective, randomized, controlled clinical trial designed to evaluate the optimal timing of midazolam administration in children undergoing adenotonsillectomy. The study will be conducted at the Departments of Otorhinolaryngology and Anesthesiology of Erzurum City Hospital.

Midazolam is commonly used in pediatric patients to reduce anxiety and improve perioperative comfort. However, the optimal timing of its administration (before surgery or during anesthesia induction) remains unclear. This study aims to compare the effects of preoperative oral midazolam and intraoperative intravenous midazolam on stress response, behavioral outcomes, and recovery quality.

Participants will be randomly assigned to one of two groups. In Group A, children will receive oral midazolam (0.5 mg/kg) 30 minutes before surgery. In Group B, children will receive intravenous midazolam (0.05-0.1 mg/kg) during anesthesia induction.

The primary outcome of the study is the change in serum cortisol levels, which reflects the physiological stress response. Blood samples will be collected twice: once 10 minutes after anesthesia induction and once 15 minutes after surgery in the post-anesthesia care unit.

In addition to cortisol levels, the study will assess preoperative anxiety using an observational anxiety scale, postoperative pain using a behavioral pain scoring system, and parental satisfaction using a standardized questionnaire. These measures aim to provide a comprehensive evaluation of the child's perioperative experience.

The findings of this study may help determine the most effective timing of midazolam administration to reduce stress, improve recovery, and enhance overall patient and family satisfaction in pediatric surgical care.

Visão geral do estudo

Descrição detalhada

This study is a prospective, randomized, controlled clinical trial designed to evaluate the effects of the timing of midazolam administration on physiological stress response, behavioral anxiety, postoperative pain, recovery quality, and parental satisfaction in pediatric patients undergoing elective adenotonsillectomy.

The primary objective is to compare the effect of midazolam administration timing on physiological stress response, assessed by serum cortisol levels. Secondary objectives include evaluating preoperative anxiety levels, postoperative pain scores, recovery quality, and parental satisfaction between groups receiving midazolam at different time points.

The study will include children aged 3-10 years, classified as ASA physical status I-II, scheduled for elective adenoidectomy, tonsillectomy, or adenotonsillectomy.

Eligible patients will be identified during preoperative anesthesia evaluation. Parents or legal guardians will be informed about the study, and written informed consent will be obtained prior to enrollment.

Participants will be randomly assigned to one of two groups using a computer-generated randomization sequence with sealed envelope allocation:

Group A (Preoperative Midazolam Group): Patients will receive oral midazolam (0.5 mg/kg) 30 minutes before surgery, administered with a small volume of apple juice under clinical supervision.

Group B (Intraoperative Midazolam Group): Patients will receive intravenous midazolam (0.05-0.1 mg/kg) during anesthesia induction.

Anesthesia Protocol

To ensure comparability between groups, all patients will undergo a standardized anesthesia protocol. Vascular access will be established after inhalational induction using sevoflurane in oxygen, minimizing stress associated with intravenous cannulation.

Lidocaine (0.5-1 mg/kg) will be administered prior to propofol injection to reduce injection pain Propofol (2-3 mg/kg) will be used for induction Rocuronium (0.6 mg/kg) will be administered for neuromuscular blockade Fentanyl (1-2 µg/kg) will be used for analgesia

Anesthesia maintenance will be achieved with sevoflurane (2-3%) in a mixture of oxygen and air, targeting an age-adjusted MAC ≥1.3. Mechanical ventilation will be standardized with volume-controlled settings appropriate for age.

Intraoperative fluid management will be based on body weight using standard pediatric maintenance formulas and isotonic saline solution.

Neuromuscular blockade will be reversed with sugammadex (2 mg/kg) Extubation will be performed based on clinical recovery criteria, including adequate spontaneous respiration and responsiveness

All patients will receive intravenous paracetamol (10-15 mg/kg) for postoperative analgesia and ondansetron (0.1 mg/kg) for prophylaxis of nausea and vomiting.

Serum cortisol levels will be measured at two time points:

Intraoperative period (10 minutes after anesthesia induction) Early postoperative period (15 minutes after admission to the post-anesthesia care unit)

Cortisol levels will be analyzed using an electrochemiluminescence immunoassay method.

Preoperative anxiety will be assessed using a modified observational anxiety scale. Postoperative pain will be evaluated using a validated behavioral pain scoring system, and recovery status will be assessed using standard recovery criteria.

Parental satisfaction will be evaluated within the first 30 minutes after surgery using a structured questionnaire assessing overall perioperative experience.

All perioperative data will be recorded by the anesthesia team and post-anesthesia care unit staff. Collected data will be analyzed statistically to compare outcomes between the two groups.

Tipo de estudo

Intervencional

Inscrição (Estimado)

100

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Yakutiye
      • Erzurum, Yakutiye, Turquia (Türkiye), 25240
        • Erzurum City Hospital
        • Subinvestigador:
          • Ahmet Ergün, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Children aged 3-10 years,
  • Scheduled for elective adenoidectomy, tonsillectomy, or adenotonsillectomy,
  • American Society of Anesthesiologists (ASA) physical status I-II,
  • Written informed consent obtained from parents or legal guardians

Exclusion Criteria:

  • Children younger than 3 years or older than 10 years,
  • American Society of Anesthesiologists (ASA) physical status greater than II,
  • Known allergy to apple or apple-derived products,
  • Known allergy or hypersensitivity to benzodiazepines,
  • Presence of developmental delay,
  • History of neuropsychiatric disorders,
  • Current or recent use of corticosteroids,
  • Expected or actual surgical duration longer than 90 minutes,
  • Refusal of participation by parents or legal guardians

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Preoperative Oral Midazolam
Participants in this group will receive oral midazolam at a dose of 0.5 mg/kg, administered 30 minutes before surgery. The medication will be mixed with a small volume of apple juice to facilitate administration and improve tolerance.
Oral midazolam will be administered at a dose of 0.5 mg/kg, 30 minutes before surgery. The medication will be mixed with a small volume of apple juice to facilitate administration.
Experimental: Intraoperative Intravenous Midazolam
Participants in this group will receive intravenous midazolam at a dose of 0.05-0.1 mg/kg during anesthesia induction.
Intravenous midazolam will be administered at a dose of 0.05-0.1 mg/kg during anesthesia induction.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Serum Cortisol Levels
Prazo: At 10 minutes after anesthesia induction and at 15 minutes postoperatively in the post-anesthesia care unit (PACU)
Serum cortisol levels will be measured to assess physiological stress response.
At 10 minutes after anesthesia induction and at 15 minutes postoperatively in the post-anesthesia care unit (PACU)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Preoperative Anxiety Level (mYPAS Score)
Prazo: During the preoperative period before anesthesia induction
Preoperative anxiety will be assessed using the modified Yale Preoperative Anxiety Scale (mYPAS), an observational tool evaluating behavioral anxiety in children across multiple domains. Scores will be normalized to a 0-100 scale, with higher scores indicating greater anxiety.
During the preoperative period before anesthesia induction
Postoperative Pain Score (FLACC Score)
Prazo: At 15 minutes postoperatively in the post-anesthesia care unit (PACU)
Postoperative pain will be evaluated using the FLACC (Face, Legs, Activity, Cry, Consolability) scale, a validated behavioral pain assessment tool for pediatric patients. Each category is scored from 0 to 2, with a total score ranging from 0 to 10, where higher scores indicate more severe pain.
At 15 minutes postoperatively in the post-anesthesia care unit (PACU)
Recovery Status (Modified Aldrete Score)
Prazo: Within the first 30 minutes postoperatively in the PACU
Recovery status will be assessed using the Modified Aldrete Score, which evaluates activity, respiration, circulation, consciousness, and oxygen saturation. Higher scores indicate better recovery and readiness for discharge from the PACU.
Within the first 30 minutes postoperatively in the PACU
Parental Satisfaction (PAPS Survey)
Prazo: Within 30 minutes after the child becomes clinically stable in the postoperative period
Parental satisfaction will be evaluated using the Pediatric Anesthesia Parent Satisfaction (PAPS) survey, a structured questionnaire assessing satisfaction with perioperative care, including communication, pain management, and overall experience. Scores range from 5 to 25, with higher scores indicating greater satisfaction.
Within 30 minutes after the child becomes clinically stable in the postoperative period

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Mehmet Sercan Orbak, MD, Erzurum City Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de agosto de 2026

Conclusão Primária (Estimado)

1 de agosto de 2027

Conclusão do estudo (Estimado)

1 de setembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

28 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de maio de 2026

Primeira postagem (Real)

3 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

7 de junho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data (IPD) will not be publicly available due to institutional and ethical restrictions.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Midazolam (Oral)

Se inscrever